


GP 1653



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: SHAI et al  
 Application No.: 09/367,714  
 Filed: January 14, 2000  
 For: ANTIPATHOGENIC SYNTHETIC PEPTIDES AND COMPOSITIONS COMPRISING THEM

Art Unit: 1653  
 Examiner: D. Lukton  
 Washington, D.C.  
 Atty.'s Docket: SHAI=2  
 Date: January 4, 2001

RECEIVED

JAN 09 2001

THE COMMISSIONER OF PATENTS AND TRADEMARKS  
 Washington, D.C. 20231

TECH CENTER 1600/2800

Sir:

Transmitted herewith is a [ ] Amendment [XX] RESPONSE TO RESTRICTION REQUIREMENT  
 in the above-identified application.

- [ ] Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted
- [ ] A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
- [xx] No additional fee is required.
- [ ] The fee has been calculated as shown below:

(Col. 1)		(Col. 2)		(Col. 3)	SMALL ENTITY		OR	OTHER THAN SMALL ENTITY	
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS	RATE	ADDITIONAL FEE		RATE	ADDITIONAL FEE
TOTAL	*	MINUS	** 20	0	x 9	\$		x 18	\$
INDEP.	*	MINUS	*** 3	0	x 39	\$		x 78	\$
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM					+ 130	\$		+ 260	\$
					ADDITIONAL FEE TOTAL			TOTAL	

- \* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- \*\* If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.
- \*\*\* If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time  
 If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

[ ] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity		Other Than Small Entity	
Response Filed Within		Response Filed Within	
[ ] First	- \$ 55.00	[ ] First	- \$ 110.00
[ ] Second	- \$ 190.00	[ ] Second	- \$ 380.00
[ ] Third	- \$ 435.00	[ ] Third	- \$ 870.00
[ ] Fourth	- \$ 680.00	[ ] Fourth	- \$ 1360.00
Month After Time Period Set		Month After Time Period Set	

- [ ] Less fees (\$ ) already paid for \_\_\_ month(s) extension of time on \_\_\_\_\_.
- [ ] Please charge my Deposit Account No. 02-4035 in the amount of \$ \_\_\_\_\_.
- [ ] A check in the amount of \$ \_\_\_\_\_ is attached (check no. ).

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK  
 Attorneys for Applicant(s)

Facsimile: (202) 737-3528  
 Telephone: (202) 628-5197

By:   
 ALLEN C. YUN  
 Registration No. 37,971



#14 1/12/01  
J. Bray

INVENTOR UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: SHAI=2

In re Application of:	)	Art Unit: 1653
	)	
SHAI et al.	)	Examiner: D. LUKTON
	)	
Appln. No.: 09/367,714	)	Washington, D.C.
	)	
Filed: January 14, 2000	)	January 4, 2001
	)	
For: ANTIPATHOGENIC SYNTHETIC	)	
PEPTIDES AND COMPOSITIONS	)	
COMPRISING THEM	)	

RECEIVED

JAN 09 2001

TECH CENTER 1600/2000

RESPONSE TO RESTRICTION REQUIREMENT

Honorable Director  
Washington, D.C. 20231

Sir:

The Office Action of December 12, 2000, primarily in the nature of a requirement for restriction, has been carefully reviewed.

Restriction has been required between what the examiner deems to be three patentably distinct inventions, namely:

Group I, drawn to cytolytic agents of subgenus G3, and presently comprising claims 1-5, 7-12, and 18-26;

Group II, drawn to cytolytic agents of subgenus G2, and presently comprising claims 1, 15, 16, and 22-26; and

Group III, drawn to cytolytic agents of subgenus G1, and presently comprising claims 1, 15, 16, 18, and 22-26.

Applicants hereby elect without traverse Group I, subgenus G3, presently comprising claims 1-5, 7-12, and 18-26. In addition, applicants hereby elect without traverse the peptide 24 recited in claim 12 as the elected specie. Claims 1, 7-13, 18-20, and 22-26 read on the elected specie.

It is understood however that if the elected specie is found to be allowable, then all of the species of the generic claims will be examined.

Favorable consideration is respectfully requested.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.  
Attorneys for Applicant(s)

By 

Allen C. Yun  
Registration No. 37,971

ACY:pr

624 Ninth Street, N.W.  
Suite 300  
Washington, D.C. 20001  
Telephone No.: (202) 628-5197  
Facsimile No.: (202) 737-3528  
F:\Y\YEDA\Shai2\Pto\RESPONSE TO RESTRICTION REQUIREMENT.wpd